In vitro models of the crosstalk between multiple myeloma and stromal cells recapitulate the mild NF-κB activation observed in vivo.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
06 Oct 2024
Historique:
received: 10 10 2023
accepted: 28 08 2024
revised: 21 08 2024
medline: 7 10 2024
pubmed: 7 10 2024
entrez: 6 10 2024
Statut: epublish

Résumé

Multiple myeloma (MM) is linked to chronic NF-κB activity in myeloma cells, but this activity is generally considered a cell-autonomous property of the cancer cells. The precise extent of NF-κB activation and the contributions of the physical microenvironment and of cell-to-cell communications remain largely unknown. By quantitative immunofluorescence, we found that NF-κB is mildly and heterogeneously activated in a fraction of MM cells in human BMs, while only a minority of MM cells shows a strong activation. To gain quantitative insights on NF-κB activation in living MM cells, we combined advanced live imaging of endogenous p65 Venus-knocked-in in MM.1S and HS-5 cell lines to model MM and mesenchymal stromal cells (MSCs), cell co-cultures, microfluidics and custom microbioreactors to mimic the 3D-interactions within the bone marrow (BM) microenvironment. We found that i) reciprocal MM-MSC paracrine crosstalk and cell-to-scaffold interactions shape the inflammatory response in the BM; ii) the pro-inflammatory cytokine IL-1β, abundant in MM patients' plasma, activates MSCs, whose paracrine signals are responsible for strong NF-κB activation in a minority of MM cells; iii) IL-1β, but not TNF-α, activates NF-κB in vivo in BM-engrafted MM cells, while its receptor inhibitor Anakinra reduces the global NF-κB activation. We propose that NF-κB activation in the BM of MM patients is mild, restricted to a minority of cells and modulated by the interplay of restraining physical microenvironmental cues and activating IL-1β-dependent stroma-to-MM crosstalk.

Identifiants

pubmed: 39370432
doi: 10.1038/s41419-024-07038-1
pii: 10.1038/s41419-024-07038-1
doi:

Substances chimiques

NF-kappa B 0
Interleukin-1beta 0
Transcription Factor RelA 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

731

Subventions

Organisme : Fondazione Cariplo (Cariplo Foundation)
ID : 2018-0551
Organisme : Fondazione Cariplo (Cariplo Foundation)
ID : 2018-0551
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : MFAG [ID-27415]
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : [IG-18623
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : MFAG [ID-27415]

Informations de copyright

© 2024. The Author(s).

Références

Ghobrial IM, Detappe A, Anderson KC, Steensma DP. The bone-marrow niche in MDS and MGUS: Implications for AML and MM. Nat Rev Clin Oncol. 2018;15:219–33.
pubmed: 29311715 doi: 10.1038/nrclinonc.2017.197
Liu R, Gao Q, Foltz SM, Fowles JS, Yao L, Wang JT, et al. Co-evolution of tumor and immune cells during progression of multiple myeloma. Nat Commun. 2021;12:1–18.
Musolino C, Allegra A, Innao V, Allegra AG, Pioggia G, Gangemi S Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma. Mediators Inflamm. 2017; https://doi.org/10.1155/2017/1852517 .
Gherardi RK, Bélec L, Fromont G, Divine M, Malapert D, Gaulard P, et al. Elevated levels of interleukin-1 beta (IL-1 beta) and IL-6 in serum and increased production of IL-1 beta mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome. Blood. 1994;83:2587–93.
pubmed: 8167341 doi: 10.1182/blood.V83.9.2587.2587
Nobari ST, Rasmi Y, Ansari MHK. Serum Levels of Interleukin-1β and Disease Progression in Multiple Myeloma Patients: A Case and Control Study. Asian Pac J Cancer Prev. 2022;23:2937–42.
pmcid: 9810305 doi: 10.31557/APJCP.2022.23.9.2937
Takagi S, Tsukamoto S, Park J, Johnson KE, Kawano Y, Moschetta M, et al. Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation. Clin Cancer Res. 2018;24:2430–9.
pubmed: 29440174 doi: 10.1158/1078-0432.CCR-17-2003
Matthews GM, de Matos Simoes R, Dhimolea E, Sheffer M, Gandolfi S, Dashevsky O, et al. NF-κB dysregulation in multiple myeloma. Semin Cancer Biol. 2016;39:68–76.
pubmed: 27544796 doi: 10.1016/j.semcancer.2016.08.005
Roy P, Sarkar U, Basak S. The NF-κB Activating Pathways in Multiple Myeloma. Biomedicines. 2018;6:59.
pubmed: 29772694 pmcid: 6027071 doi: 10.3390/biomedicines6020059
Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, et al. Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma. Cancer Cell. 2007;12:115–30.
pubmed: 17692804 pmcid: 2730509 doi: 10.1016/j.ccr.2007.07.004
Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, et al. Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells. Blood. 2009;114:1046–52.
pubmed: 19436050 pmcid: 2721785 doi: 10.1182/blood-2009-01-199604
Conticello C, Giuffrida R, Adamo L, Anastasi G, Martinetti D, Salomone E, et al. NF-κB localization in multiple myeloma plasma cells and mesenchymal cells. Leuk Res. 2011;35:52–60.
pubmed: 20674018 doi: 10.1016/j.leukres.2010.06.023
Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009;113:4341–51.
pubmed: 19139079 pmcid: 2676090 doi: 10.1182/blood-2008-10-186668
Moschetta M, Kawano Y, Sacco A, Belotti A, Ribolla R, Chiarini M, et al. Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing. Curr Osteoporos Rep. 2017;15:499–506.
pubmed: 28889371 doi: 10.1007/s11914-017-0399-3
de Jong MME, Kellermayer Z, Papazian N, Tahri S, Hofste op Bruinink D, Hoogenboezem R, et al. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nat Immunol. 2021;22:769–80.
pubmed: 34017122 doi: 10.1038/s41590-021-00931-3
Ghobrial IM, Liu C, Zavidij O, Azab AK, Baz R, Laubach JP, et al. Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol. 2019;94:1244–1253.
pubmed: 31456261 doi: 10.1002/ajh.25627
Zambrano S, De Toma I, Piffer A, Bianchi ME, Agresti A. NF-κB oscillations translate into functionally related patterns of gene expression. Elife. 2016;5:e09100.
pubmed: 26765569 pmcid: 4798970 doi: 10.7554/eLife.09100
Sung MH, Salvatore L, De Lorenzi R, Indrawan A, Pasparakis M, Hager GL, et al. Sustained oscillations of NF-κB produce distinct genome scanning and gene expression profiles. PLoS One 2009; 4. https://doi.org/10.1371/journal.pone.0007163 .
Ashall L, Horton CA, Nelson DE, Paszek P, Harper CV, Sillitoe K, et al. Pulsatile stimulation determines timing and specificity of NF-kappaB-dependent transcription. Science (1979). 2009;324:242–6.
Kellogg RA, Tay S. Noise Facilitates Transcriptional Control under Dynamic Inputs. Cell. 2015;160:381–92.
pubmed: 25635454 doi: 10.1016/j.cell.2015.01.013
Ihekwaba AE, Broomhead DS, Grimley R, Benson N, White MR, Kell DB. Synergistic control of oscillations in the NF-kappaB signalling pathway. Syst Biol (Stevenage). 2005;152:153–60.
pubmed: 16986278 doi: 10.1049/ip-syb:20050050
Kearns JD, Basak S, Werner SL, Huang CS, Hoffmann A. IkappaBepsilon provides negative feedback to control NF-kappaB oscillations, signaling dynamics, and inflammatory gene expression. J Cell Biol. 2006;173:659–64.
pubmed: 16735576 pmcid: 2063883 doi: 10.1083/jcb.200510155
The human protein atlas. https://www.proteinatlas.org/ .
Zambrano S, Bianchi ME, Agresti A. High-Throughput Analysis of NF-kappaB Dynamics in Single Cells Reveals Basal Nuclear Localization of NF-kappaB and Spontaneous Activation of Oscillations. PLoS One. 2014;9:e90104.
pubmed: 24595030 pmcid: 3942427 doi: 10.1371/journal.pone.0090104
Zambrano S, Bianchi ME, Agresti A. A simple model of NF-kappaB dynamics reproduces experimental observations. J Theor Biol. 2014;347:44–53.
pubmed: 24447586 doi: 10.1016/j.jtbi.2014.01.015
Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, et al. Characterization of the MM.1 human multiple myeloma (MM) cell lines: A model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol. 2003;31:271–82.
pubmed: 12691914 doi: 10.1016/S0301-472X(03)00023-7
Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia. 2001;15:1950–61.
pubmed: 11753617 doi: 10.1038/sj.leu.2402295
Roccaro AM, Mishima Y, Sacco A, Moschetta M, Tai YT, Shi J, et al. CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation. Cell Rep. 2015;12:622–35.
pubmed: 26190113 pmcid: 4961259 doi: 10.1016/j.celrep.2015.06.059
Belloni D, Heltai S, Ponzoni M, Villa A, Vergani B, Pecciarini L, et al. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment. Haematologica. 2018;103:707–16.
pubmed: 29326121 pmcid: 5865414 doi: 10.3324/haematol.2017.167486
Adamo A, Delfino P, Gatti A, Bonato A, Takam Kamga P, Bazzoni R, et al. HS-5 and HS-27A Stromal Cell Lines to Study Bone Marrow Mesenchymal Stromal Cell-Mediated Support to Cancer Development. Front Cell Dev Biol. 2020;8:1–13.
doi: 10.3389/fcell.2020.584232
Runnels JM, Carlson AL, Pitsillides C, Thompson B, Wu J, Spencer JA, et al. Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. J Biomed Opt. 2011;16:011006.
pubmed: 21280893 pmcid: 3033873 doi: 10.1117/1.3520571
Nagai T, Ibata K, Park ES, Kubota M, Mikoshiba K, Miyawaki A. A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological …. Genetics. 1989;20:1585–8.
Stewart-Ornstein J, Lahav G. Dynamics of CDKN1A in Single Cells Defined by an Endogenous Fluorescent Tagging Toolkit. Cell Rep. 2016;14:1800–11.
pubmed: 26876176 pmcid: 5154611 doi: 10.1016/j.celrep.2016.01.045
Kumar SK, Rajkumar V, Kyle RA, Van Duin M, Sonneveld P, Mateos MV, et al. Multiple myeloma. Nat Rev Dis Prim. 2017;3:17046.
pubmed: 28726797 doi: 10.1038/nrdp.2017.46
Yılmaz ZB, Kofahl B, Beaudette P, Baum K, Ipenberg I, Weih F, et al. Quantitative Dissection and Modeling of the NF-κB p100-p105 Module Reveals Interdependent Precursor Proteolysis. Cell Rep. 2014;9:1756–69.
pubmed: 25482563 doi: 10.1016/j.celrep.2014.11.014
Meier-Soelch J, Mayr-Buro C, Juli J, Leib L, Linne U, Dreute J, et al. Monitoring the Levels of Cellular NF-κB Activation States. Cancers (Basel). 2021;13:5351.
pubmed: 34771516 doi: 10.3390/cancers13215351
Caldwell AB, Cheng Z, Vargas JD, Birnbaum HA, Hoffmann A. Network dynamics determine the autocrine and paracrine signaling functions of TNF. Genes Dev. 2014;28:2120–33.
pubmed: 25274725 pmcid: 4180974 doi: 10.1101/gad.244749.114
Lee RE, Walker SR, Savery K, Frank DA, Gaudet S. Fold change of nuclear NF-kappaB determines TNF-induced transcription in single cells. Mol Cell. 2014;53:867–79.
pubmed: 24530305 pmcid: 3977799 doi: 10.1016/j.molcel.2014.01.026
Kellogg RA, Tian C, Lipniacki T, Quake SR, Tay S. Digital signaling decouples activation probability and population heterogeneity. Elife. 2015;4:1–26.
doi: 10.7554/eLife.08931
Lee TK, Denny EM, Sanghvi JC, Gaston JE, Maynard ND, Hughey JJ et al. A Noisy Paracrine Signal Determines the Cellular NF-κB Response to Lipopolysaccharide. Sci Signal 2009; 2. https://doi.org/10.1126/scisignal.2000599 .
Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM. Classical and / or alternative NF-kB pathway activation in multiple myeloma. Cancer. 2010;115:3541–52.
Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471:467–72.
pubmed: 21430775 pmcid: 3560292 doi: 10.1038/nature09837
Lawson MA, McDonald MM, Kovacic N, Khoo WH, Terry RL, Down J, et al. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 2015;6:8983.
pubmed: 26632274 doi: 10.1038/ncomms9983
Visone R, Talò G, Occhetta P, Cruz-Moreira D, Lopa S, Pappalardo OA, et al. A microscale biomimetic platform for generation and electro-mechanical stimulation of 3D cardiac microtissues. APL Bioeng 2018; 2. https://doi.org/10.1063/1.5037968 .
Verbruggen SW, Freeman CL, Freeman FE Utilizing 3D Models to Unravel the Dynamics of Myeloma Plasma Cells’ Escape from the Bone Marrow Microenvironment. Cancers (Basel). 2024; 16. https://doi.org/10.3390/cancers16050889 .
Lust JA, Lacy MQ, Zeldenrust SR, Witzig TE, Moon-Tasson LL, Dinarello CA, et al. Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma. Am J Hematol. 2016;91:571–4.
pubmed: 26945843 doi: 10.1002/ajh.24352
Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc. 2009;84:114–22.
pubmed: 19181644 pmcid: 2664581 doi: 10.4065/84.2.114
Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain MCAR. T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24:731–8.
pubmed: 29808005 pmcid: 6410714 doi: 10.1038/s41591-018-0041-7
Lohr JG, Kim S, Gould J, Knoechel B, Drier Y, Cotton MJ, et al. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med. 2016;8:363ra147–363ra147.
pubmed: 27807282 pmcid: 5426804 doi: 10.1126/scitranslmed.aac7037
Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, et al. The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep. 2017;19:218–24.
pubmed: 28380360 pmcid: 5439509 doi: 10.1016/j.celrep.2017.03.025
Shen YJ, Mishima Y, Shi J, Sklavenitis-Pistofidis R, Redd RA, Moschetta M, et al. Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood. 2021;137:2360–72.
pubmed: 33150374 pmcid: 8085483 doi: 10.1182/blood.2020005885
Székely T, Burrage K, Mangel M, Bonsall MB. Stochastic Dynamics of Interacting Haematopoietic Stem Cell Niche Lineages. PLoS Comput Biol. 2014;10:e1003794.
pubmed: 25188267 pmcid: 4154659 doi: 10.1371/journal.pcbi.1003794
Christodoulou C, Spencer JA, Yeh SCA, Turcotte R, Kokkaliaris KD, Panero R, et al. Live-animal imaging of native haematopoietic stem and progenitor cells. Nature. 2020;578:278–83.
pubmed: 32025033 pmcid: 7021587 doi: 10.1038/s41586-020-1971-z
Méndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, MacArthur BD, Lira SA, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466:829–34.
pubmed: 20703299 pmcid: 3146551 doi: 10.1038/nature09262
Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25:91–101.
pubmed: 24434212 pmcid: 4241387 doi: 10.1016/j.ccr.2013.12.015
Vangsted AJ, Klausen TW, Ruminski W, Gimsing P, Andersen NF, Gang AO, et al. The polymorphism IL-1 b T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT. 2009;43:539–45.
Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749–59.
pubmed: 16175180 doi: 10.1038/nri1703
Caronni N, La Terza F, Vittoria FM, Barbiera G, Mezzanzanica L, Cuzzola V, et al. IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer. Nature. 2023;623:415–22.
pubmed: 37914939 doi: 10.1038/s41586-023-06685-2
Sun J, Park C, Guenthner N, Gurley S, Zhang L, Lubben B et al. Tumor-associated macrophages in multiple myeloma: Advances in biology and therapy. J Immunother Cancer. 2022; 10. https://doi.org/10.1136/jitc-2021-003975 .
Beyar-Katz O, Magidey K, Reiner-Benaim A, Barak N, Avivi I, Cohen Y, et al. Proinflammatory macrophages promote multiple myeloma resistance to bortezomib therapy. Mol Cancer Res. 2019;17:2331–40.
pubmed: 31409628 doi: 10.1158/1541-7786.MCR-19-0487
Xiong Y, Donovan KA, Kline MP, Gornet MK, Moon-Tasson LL, Lacy MQ, et al. Identification of Two Groups of Smoldering Multiple Myeloma Patients Who Are Either High or Low Producers of Interleukin-1. 2006 www.liebertpub.com .
de Jong MME, Fokkema C, Papazian N, Czeti Á, Appelman MK, Vermeulen M, et al. An IL-1β-driven neutrophil–stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma. Nat Immunol. 2024. https://doi.org/10.1038/s41590-024-01808-x .
Damasceno D, Almeida J, Teodosio C, Sanoja‐flores L, Mayado A, Pérez‐pons A, et al. Monocyte subsets and serum inflammatory and bone-associated markers in monoclonal gammopathy of undetermined significance and multiple myeloma. Cancers (Basel). 2021;13:1–18.
doi: 10.3390/cancers13061454
Aaron T, Laudermilch E, Benet Z, Ovando LJ, Chandran K, Fooksman D. TNF-α Limits Serological Memory by Disrupting the Bone Marrow Niche. J Immunol. 2023;210:595–608.
pubmed: 36645344 doi: 10.4049/jimmunol.2200053
Capp JP, Bataille R A bone paradigm challenging the standard model of myeloma oncogenesis. Crit Rev Oncol Hematol. 2022; 172. https://doi.org/10.1016/j.critrevonc.2022.103640 .
Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature. 2017;546:431–5.
pubmed: 28607484 pmcid: 5542814 doi: 10.1038/nature22794
Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: An open-source platform for biological-image analysis. Nat Methods. 2012;9:676–82.
pubmed: 22743772 doi: 10.1038/nmeth.2019
Macosko EZ, Basu A, Satija R, Nemesh J, Shekhar K, Goldman M, et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell. 2015;161:1202–14.
pubmed: 26000488 pmcid: 4481139 doi: 10.1016/j.cell.2015.05.002

Auteurs

Federica Colombo (F)

Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.
Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.

Virginia Guzzeloni (V)

Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
Universita' Vita-Salute San Raffaele, Milan, Italy.

Cise Kizilirmak (C)

Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.

Francesca Brambilla (F)

Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.

Jose Manuel Garcia-Manteiga (JM)

Center for Omics Sciences, IRCCS Ospedale San Raffaele, Milan, Italy.

Anna Sofia Tascini (AS)

Universita' Vita-Salute San Raffaele, Milan, Italy.
Center for Omics Sciences, IRCCS Ospedale San Raffaele, Milan, Italy.

Federica Moalli (F)

Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy.

Francesca Mercalli (F)

Hospital "Maggiore della Carità", Unit of Pathology, Novara, Italy.

Maurilio Ponzoni (M)

Universita' Vita-Salute San Raffaele, Milan, Italy.

Rosanna Mezzapelle (R)

Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.
Universita' Vita-Salute San Raffaele, Milan, Italy.

Marina Ferrarini (M)

B-Cell Neoplasia Unit, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.

Elisabetta Ferrero (E)

B-Cell Neoplasia Unit, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.

Roberta Visone (R)

Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.

Marco Rasponi (M)

Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.

Marco E Bianchi (ME)

Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.
Universita' Vita-Salute San Raffaele, Milan, Italy.

Samuel Zambrano (S)

Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy. zambrano.samuel@hsr.it.
Universita' Vita-Salute San Raffaele, Milan, Italy. zambrano.samuel@hsr.it.

Alessandra Agresti (A)

Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy. agresti.alessandra@hsr.it.
Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy. agresti.alessandra@hsr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH